4DMT Reports 2-Year SPECTRA Data and Details 4SIGHT Phase 3 DME Trial Design
FDMT has more than doubled off its 52-week low of $6.96.
Summary
4DMT disclosed 2-year SPECTRA data showing durable efficacy and safety for 4D-150 in DME, plus detailed 4SIGHT Phase 3 trial design with FDA/EMA alignment on a single-trial regulatory pathway.
Key Events · Product Development and Regulatory · FDMT
-
2-Year SPECTRA Data Show Durable Efficacy
Phase 3 dose (3E10 vg/eye, n=9) achieved mean +10.8 letters BCVA gain and -176 µm CST reduction at 2 years, with no intraocular inflammation or ocular serious adverse events.
-
Treatment Burden Reduced 61%
Patients required 5.2 mean supplemental injections vs. 13.0 projected with on-label aflibercept Q8W; 75% estimated reduction using 4SIGHT criteria; 22% remained injection-free.
-
4SIGHT Phase 3 Trial Design Confirmed
Global N=514 trial in treatment-naïve DME patients, aflibercept 2mg Q8W comparator, primary endpoint non-inferiority in BCVA at Week 52, with key secondary endpoints of treatment burden reduction and ≥2-step ETDRS-DRSS improvement.
-
Regulatory Pathway Aligned with FDA and EMA
4D-150 holds FDA RMAT designation for DME; company has alignment with both agencies on potential BLA/MAA filings using the single 4SIGHT Phase 3 trial combined with SPECTRA, PRISM, and 4FRONT data.
Analysis · FDMT · Life Sciences
The 8-K provides the first detailed look at 2-year SPECTRA data for 4D-150 in diabetic macular edema, showing a +10.8 letter BCVA gain and 61% treatment burden reduction with no intraocular inflammation. It also confirms FDA and EMA alignment on a single Phase 3 trial for potential BLA/MAA filings, which materially de-risks the DME program and expands the addressable market beyond wet AMD.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FDMT was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $799.4M. The 52-week trading range was $6.96 to $16.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.